Triple Negative Invasive Breast Carcinoma: Incidence and Clinical - Pathological Characteristics
Versión traducida del artículo "Carcinomas invasores triples negativos de la glándulamamaria: incidencia y características clínico-patológicas" DOI: https://doi.org/10.51481/amc.v52i2.641
Palabras clave:breast cancer, triple-negative, immunohistochemistry, progesterone and estrogen receptors, HER-2
Aim: The epidemiological behavior of malignant tumors in Costa Rica has undergone an important change during the last years; breast carcinoma has increased its incidence, occupying the second place in malignancies in women and the first one in mortality. This type of tumor can be studied by several immunohistochemistry markers, such as the expression of different hormonal receptors by neoplastic cells (estrogen receptors, progesterone receptors and Human Epidermal Growth-Factor Receptor type 2, HER2). Carcinomas which do not express any of these three receptors have a worse prognosis. Objectives for this study were to determine the main characteristics of these tumors, named triple negative carcinomas, and to define their relevance within breast carcinomas.
Methodology: Data was collected from all women with breast cancer diagnosed, with immunohistochemistry studies, from January 1st, to December 31st, 2006, at the Pathology Department of the San Juan de Dios Hospital. Patient´s age, histological type and degree of differentiation, were taken into account for each case. Triple negative carcinomas were considered separately, and statistical analysis was made with Epi Info 3.3.4 software.
Results: During the above mentioned period, 221 patients were diagnosed with breast cancer, 40 of them were identified as having triple negative carcinomas, which meant an incidence of 18% (C.I. 95%, 12.79 – 23.40), and had an average of 54 years old (C.I. 95%, 50 - 58 ), a median of 52 years old and a mode of 48 years old. Triple-negative cancer was more related with ductal infiltrating histological type: 67.5% (C.I. 95%, 51.73-83.26), followed by infiltrating lobular, with 12.5% (C.I. 95%, 4.18 – 26.80), medullary, with 5%, and less related are papillary type and spindle cell metaplastic carcinoma. According to the degree of differentiation, there were 23 grade-3 cases, 8 grade-2 cases,
and 3 grade-1 carcinomas.
Conclusion: Triple negative breast cancers are an aggressive group of tumors, which manifest at younger ages, have larger tumor size, are of higher histological grade, and mostly are infiltrating ductal carcinomas. Due to the fact that this was based only on determination of hormonal receptors and HER2, other tests might be necessary such as CK5/6 and 17 stains to check basal-like carcinoma cases. Also, this study shows a higher prevalence for infiltrating lobular carcinomas than other studies, so that other tests could be done such as e-cadherin, to verify the cases of lobular carcinomas, thereby increasing reliability of results.
Ministerio de Salud Pública. Incidencia de tumores malignos más frecuentes en mujeres en Costa Rica 1995-2006. Unidad de Estadística, Registro Nacional de Tumores. 2008
Rosen P. Patología mamaria de Rosen. Seg. ed. Venezuela: Editorial AMOLCA. 2005.
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001; 98:10869–10874.
Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol. 2002; 29: 231-245.
Alejandro C. Gene expression profiles for therapeutic decisions in breast cancer. Rev. méd Chile. 2007; 135: 257-263.
Mocellin S, Provenzano M, Rossi CR, Pilati P, Nitti D, Lise M. DNA array-based gene profiling: from surgical specimen to the molecular portrait of cancer. Ann Surg. 2005; 241: 16-26.
van’t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature.
; 415: 530-536.
Cleator S, Heller W, Coombes C. Triple negative breast cancer: therapeutic options. Lancet Oncol. 2007; 8: 235–244.
Bauer K, Brown M, Cress R, Parise C, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and HER2-negative invasive breast cancer, the socalled triple-negative phenotype. Cancer. 2007; 109: 1721-1729.
Nelson HD, Fuman LH, Fu R, Harris EL. Genetic risk assessment and BRCA Mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. preventive services task force. Ann Intern Med. 2005; 143:362-379.
Análisis Epidemiológico de Datos Tabulados (EPIDAT): Organización Mundial de la Salud, Organización Panamericana de la Salud. En: http://www.paho.org/Spanish/SHA/epidat.htm
Jiménez G, Villalobos M, Jiménez E, Palma W. Determinación de la efectividad de cinco protocolos de extracción de ADN a partir de material parafinado para estudios moleculares. Rev med UCR. 2007; 1: 10-19.
Rakha E.A. Morphology and immunophenotypic analysis of breast carcinoma with basal and myoepithelial differentiation. J Pathology. 2006; 208: 495-506.
Mi -Jung Kim, Jae Y. Ro, Sei-Hyun Ahn, Hak Hee Kim, Sung Bae Kim, Gyungyub Gong. Clinicopathologic significance of the basallike subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Human Pathology. 2006; 37: 1217–1226.
Spitale A, Mazzola P, Soldini D, Mazzuccheli L, Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol.
Derechos de autor 2010 Acta Médica Costarricense
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)